GlassScriptPhysician profile
Kiritkumar A Parmar
NPI 1396813614
$2,191.00
in general payments reported to CMS, 2019-2025
28 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $268 · 2021: $323 · 2022: $286 · 2023: $346 · 2024: $264 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $530.19 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.13 | 2019-2023 | Jardiance, Tradjenta |
| Lilly USA, LLC | $155.78 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Abbott Laboratories | $125.36 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $124.47 | 2020-2024 | |
| Amgen INC. | $124.13 | 2023-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $101.59 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $100.41 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $99.44 | 2019-2022 | |
| Abbvie INC. | $61.36 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $55.43 | 2019 | |
| Exact Sciences Corporation | $54.31 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boston Scientific Corporation | $52.75 | 2024-2025 | Watchman Flx, Watchman Access System |
| Sunovion Pharmaceuticals INC. | $46.39 | 2019 | |
| Philips North America LLC | $44.86 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $39.19 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.17 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $32.66 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $28.76 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $26.35 | 2019-2020 | |
| Astellas Pharma US INC | $26.20 | 2019 | |
| Soleno Therapeutics, INC. | $24.88 | 2025 | Vykat Xr |
| Xeris Pharmaceuticals, INC. | $17.68 | 2023 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $14.04 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $13.49 | 2025 | Gemtesa |
| Sun Pharmaceutical Industries INC. | $12.60 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.90 | 2019 | |
| Daiichi Sankyo INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiritkumar Parmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.